BCR/ABL QUANTITATIVE (MBCR-CML)

Description

BCR/ABL quantitative testing, specifically targeting the M-BCR breakpoint in Chronic Myeloid Leukemia (CML), is a crucial molecular test used to monitor the disease’s response to treatment and assess minimal residual disease. It helps determine if the treatment is effectively reducing the presence of leukemic cells and if the disease is in remission or potentially recurring.